Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth EngineSeeking Alpha · 3 days ago
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026PRNewsWire · 6 days ago
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PRNewsWire · Oct 2, 2026
Reviewing Rigel Pharmaceuticals (NASDAQ:RIGL) & Regeneron Pharmaceuticals (NASDAQ:REGN)Defense World · Oct 2, 2026
Rigel to Participate in Upcoming September Investor ConferencesPRNewsWire · Sep 2, 2026
18,800 Shares in Rigel Pharmaceuticals, Inc. $RIGL Bought by Canada Pension Plan Investment BoardDefense World · Sep 2, 2026Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | $0.09 | $0.88 | Beat |
| May 5, 2026 | $0.74 | $0.44 | Miss |
| Mar 3, 2026 | $1.33 | $1.14 | Miss |
| Nov 4, 2025 | $0.93 | $1.46 | Beat |
| Aug 5, 2025 | $1.97 | $3.28 | Beat |
| May 6, 2025 | $0.14 | $0.63 | Beat |